CSL Behring to Acquire uniQure’ Hemophilia B Candidate (AMT-061) for ~$2B

 CSL Behring to Acquire uniQure’ Hemophilia B Candidate (AMT-061) for ~$2B

CSL Behring to Acquire uniQure’ Heamophilia B Candidate (AMT-061) for ~$2B

Shots:

  • uniQure to receive $2B+ including $450M as up front in cash, $1.6B as regulatory & commercial milestones along with royalties in sales of  AMT-061 (etranacogene dezaparvovec) while CSL Behring to get an exclusive global right to commercialize AMT-061
  • uniQure will be responsible for the completion of the P-III HOPE-B study and scale-up manufacture for early commercial supply under an agreed plan with CSL Behring. uniQure will lead clinical development and regulatory activities, reimbursed by CSL Behring
  • The collaboration will foster CSL Behring’s gene therapy portfolio while allowing uniQure to expand and accelerate pipeline and platform. The AMT-061 consists of an AAV5 viral vector carrying a gene cassette with FIX-Padua, currently being evaluated in P-III study and could be one of the first gene therapies to provide long-term benefits to patients with hemophilia B

Click here, Click here to read full press release/ article | Ref: CSL Behring, Businesswire | Image: Norwood

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post